Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of AVE5530 When Added to Ongoing Stable Statin Therapy at High Doses in Patients With Severe Primary Hypercholesterolemia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Canosimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database.
- 27 Jun 2012 Planned number of patients changed from 600 to 668 as reported by European Clinical Trials Database.
- 13 Nov 2009 Actual patient number (643) added as reported by ClinicalTrials.gov.